Abstracts tagged "quality of life"

Abstract Number: 1378 • ACR Convergence 2023
The UCSD Shortness of Breath Questionnaire Is a Useful Tool for the Assessment of Dyspnea in Primary Sjögren’s Syndrome Patients with Interstitial Lung Disease: A Monocentric Cross-Sectional Study
Gaetano La Rocca¹, Francesco Ferro², Elena Elefante³, Silvia Fonzetti⁴, Giovanni Fulvio⁵, Inmaculada Conception Navarro Garcia³, Chiara Romei⁶, Marta Mosca³ and Chiara Baldini⁵, ¹University of Pisa, Rheumatology Unit, Pisa, Italy, ²Clinical and Experimental Medicine Department, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy, ³Rheumatology Unit, Department of clinical and experimental medicine, University of Pisa, Pisa, Italy, ⁴AOUP, Pisa, Italy, ⁵University of Pisa, Pisa, Italy, ⁶Department of Diagnostic Imaging, Diagnostic Radiology 2, Pisa University Hospital, Pisa, Italy
Background/Purpose: In clinical trials investigating new drugs for the management of Interstitial Lung Disease (ILD) patient reported outcomes (PRO) are increasingly employed as outcome measures…
Abstract Number: 2029 • ACR Convergence 2023
Health-Related Quality of Life in Idiopathic Inflammatory Myopathies: How to Act for Improving the Disease Burden of Patients?
Chiara Cardelli¹, Simone Barsotti², Elenia Laurino¹, Michele Diomedi¹, Federico Fattorini¹, Dina Zucchi³, Alessandra Tripoli¹, Linda Carli¹ and Marta Mosca¹, ¹Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, ²Internal Medicine, Ospedale di Livorno, Pisa, Italy, ³Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy; Department of Medical Biotechnologies, University of Siena, Pisa, Italy
Background/Purpose: Idiopathic Inflammatory Myopathies (IIM) are rare, multisystemic and complex diseases that strongly impact the Quality of Life (QoL) of those affected. Patient Reported Outcomes…
Abstract Number: 2579 • ACR Convergence 2023
Validation of PROMIS in Adult and Pediatric Patients with Idiopathic Inflammatory Myopathies
Emma Austenfeld¹, Sara Sabbagh¹, Melodee Liegl¹, Ke Yan¹, Julie Fuller², Kelly Rouster-Stevens³, Lisa Rider⁴ and Adam Schiffenbauer⁴, ¹Medical College of Wisconsin, Wauwatosa, WI, ²UT Southwestern and Scottish Rite for Children, Dallas, TX, ³Emory University/Children's Healthcare of Atlanta, Norcross, GA, ⁴NIEHS, NIH, Bethesda, MD
Background/Purpose: This study aimed to validate the Patient Reported Outcome Measurement Information System (PROMIS) tools in patients with adult and juvenile idiopathic inflammatory myopathies (IIM/JIIM)…
Abstract Number: 0374 • ACR Convergence 2023
Actionable Adverse Events in a Real-Practice Cohort of Children with Juvenile Idiopathic Arthritis. Results from the CAPRI Registry
Bashayer Alnuaimi¹, Michelle Batthish², Roberta A Berard³, Gilles Boire⁴, Sarah Campillo¹, Amieleena Chhabra⁵, Julie Couture⁶, Paul Dancey⁷, Brian Feldman⁸, Tommy Gerschman⁹, Julie Herrington¹⁰, Kristin Houghton¹¹, Adam Huber¹², Claire LeBlanc¹, Lillian Lim¹³, Jean-Philippe Proulx-Gauthier⁶, Heinrike Schmeling¹⁴, Rosie Scuccimarri¹, Lori Tucker¹⁵, Jaime Guzman¹⁵, Gaëlle Chédeville¹ and For The CAPRI Registry Investigators¹⁶, ¹McGill University Health Center, Montreal, QC, Canada, ²McMaster Children's Hospital, Hamilton, ON, Canada, ³Children's Hospital - London Health Sciences Centre, London, ON, Canada, ⁴Université de Sherbrooke, Sherbrooke, QC, Canada, ⁵British Columbia Hospital, Vancouver, BC, Canada, ⁶CHU de Quebec- Universite Laval, Quebec City, QC, Canada, ⁷Memorial University of Newfoundland, St. John's, NL, Canada, ⁸The Hospital for Sick Children, Toronto, ON, Canada, ⁹British Columbia Children's Hospital, Burnaby, BC, Canada, ¹⁰McMaster University, Hamilton, ON, Canada, ¹¹British Columbia University, Vancouver, BC, Canada, ¹²IWK Health Centre, Halifax, NS, Canada, ¹³University of Alberta, Edmonton, AB, Canada, ¹⁴University of Calgary, Calgary, AB, Canada, ¹⁵British Columbia Children's Hospital, Vancouver, BC, Canada, ¹⁶CAPRI, Montreal, QC, Canada
Background/Purpose: Juvenile idiopathic arthritis (JIA) is the most common chronic inflammatory rheumatic disease of childhood and most children require long-term treatment. Adverse events (AE) during…
Abstract Number: 0828 • ACR Convergence 2023
Item Reduction and Validation of the Cutaneous Lupus Erythematosus Quality of Life Questionnaire
Maya Adams¹, Linda Hynan², Motolani Ogunsanya³ and Benjamin Chong¹, ¹University of Texas Southwestern Medical Center, Dallas, TX, ²Peter O’Donnell Jr. School of Public Health and Department of Psychiatry, Dallas, TX, ³University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: Cutaneous lupus erythematosus (CLE) symptoms often require patient-reported outcome measures (PROMs) to monitor disease progression. The CLE quality of life (CLEQoL) instrument was devised…
Abstract Number: 1383 • ACR Convergence 2023
Long-term Association Between Physical Activity and Global Functioning in Patients with axSpA: Results of a 2 Year Prospective Study
Kwi Young Kang¹ and Hyoun-Ah Kim², ¹Catholic University of Korea, Seoul, South Korea, ²Ajou University School of Medicine, Suwon, South Korea
Background/Purpose: To assess the longitudinal association between physical activity and global functioning in patients with axial spondyloarthritis (axSpA) and to identify the subtype of physical…
Abstract Number: 2035 • ACR Convergence 2023
Intimate Partner Violence Is Associated with a Poorer Health-Related Quality of Life (HR-QoL) in Women with Systemic Lupus Erythematous
Emmanuel Campos-Tinajero¹, Griselda Serna-Peña², Jorge A. Esquivel-Valerio¹, Rodrigo J. Castillo-de la Garza³, Gisela García Arellano⁴, Pablo Gamez-Siller¹, Estefania Aguilar-Rivera⁵, Patricia L. Gonzalez-Garcia¹ and Dionicio A. Galarza-Delgado⁶, ¹Hospital Universitario "Dr. José Eleuterio González", Monterrey, Mexico, ²Universidad Autónoma de Nuevo León, Guadalupe, Mexico, ³Universidad Autónoma de Nuevo León, Monterrey, Mexico, ⁴Hospital Universitario "Dr. José Eleuterio González", Monterrey, Mexico, ⁵Hospital Universitario "Dr. José Eleuterio González", Universidad Autónoma de Nuevo León, Monterrey, Mexico, ⁶Hospital Universitario UANL, Monterrey, Mexico
Background/Purpose: Systemic lupus erythematosus (SLE) is an inflammatory, multisystemic, chronic disease more prevalent in women and can significantly impact health-related quality of life (HRQoL).1 Sociodemographic…
Abstract Number: PP03 • ACR Convergence 2023
Lupus with Slime: Improve QOL and Increase ROM in SLE with Slime
Amanda Greene, Los Angeles, CA
Background/Purpose: In 1983, over forty years ago, I was diagnosed with Systemic Lupus Erythematosus (SLE). I was immediately prescribed high dose corticosteroids. My body and…
Abstract Number: 0375 • ACR Convergence 2023
Treatment of Methotrexate Intolerance in Juvenile Idiopathic Arthritis Using Eye Movement Desensitization and Reprocessing (EMDR) Can Be Improved by Bi-lateral Alternating Stimulation Tactile (BLAST) Armbands
Lea Höfel, Bruno Eppler, Johannes-Peter Haas and Boris Hugle, German Center for Pediatric and Adolescent Rheumatology, Garmisch-Partenkirchen, Germany
Background/Purpose: Methotrexate (MTX) is commonly used in the treatment of children with juvenile idiopathic arthritis (JIA), and intolerance to the drug frequently leads to discontinuation…
Abstract Number: 0966 • ACR Convergence 2023
The Burden of Oligoarticular Psoriatic Arthritis in the United States
Abisola Olopoenia¹, Ashley Martin², Kate Orroth³, Cynthia Deignan⁴, Myriam Cordey⁵ and Dafna Gladman⁶, ¹Cerner Enviza, North Kansas City, MO, ²BluePath Solutions, Los Angeles, CA, ³Amgen, Inc., Manhattan Beach, CA, ⁴Amgen, Inc., Agoura Hills, CA, ⁵Amgen, Inc., Thousand Oaks, CA, ⁶Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Department of Medicine, University of Toronto, Toronto, ON, Canada
Background/Purpose: Patients with oligoarticular psoriatic arthritis (oligo PsA), defined as four or less joints involved, often do not meet criteria for entry in trials of…
Abstract Number: 1460 • ACR Convergence 2023
Impact of Neuropsychiatric Involvement on Health-related Quality of Life in Patients with Systemic Lupus Erythematosus
Dionysis Nikolopoulos¹, Nursen Cetrez², Julius Lindblom² and Ioannis Parodis², ¹Karolinska Institutet and Karolinska University Hospital, Division of Rheumatology, Department of Medicine Solna, Stockholm, Sweden, ²Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Substantial proportions of systemic lupus erythematosus (SLE) patients report severe fatigue and adverse Health-related Quality of Life (HRQoL). Particularly neuropsychiatric manifestations have been associated…
Abstract Number: 2112 • ACR Convergence 2023
Physical Activity in a Cohort of Patients with Rheumatoid Arthritis
Patricia Dominguez Leiva¹, Joan Manuel Dapeña¹, Juan Manuel Bande¹, Maria Alejandra Medina¹, José caracciolo¹, Diana Klajn¹, Julieta Morbiducci², Anastasia Secco³, Julia Sosa⁴, María Paula Kohan⁴, Dora Pereira⁵ and Silvia Papasidero¹, ¹Hospital General de Agudos Dr. Enrique Tornú, Buenos Aires, Argentina, ²Hospital General de Agudos Bernardino Rivadavia, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina, ³Hospital General de Agudos Bernardino Rivadavia, Ciudad Autónoma de Buenos Aires, CABA, Argentina, ⁴Hospital Raúl F. Larcade, Provincia de Buenos Aires, Buenos Aires, Argentina, ⁵Instituto Raquis, La Plata, Argentina
Background/Purpose: Physical activity has numerous benefits for Rheumatoid Arthritis (RA) patients such as reducing symptoms like fatigue and pain and improving physical function. The International…
Abstract Number: PP06 • ACR Convergence 2023
Dana’s Data Dashboard: Applying a Familiar Framework for Efficient and Effective Health Management
Dana Guglielmo, Los Angeles, CA
Background/Purpose: As a researcher and data analyst, I enjoy the meticulous attention to detail that my work requires. I love the process of collecting, analyzing,…
Abstract Number: 0397 • ACR Convergence 2023
Obesity Is Associated with Worse Flare Symptoms and Quality of Life in Early Rheumatoid Arthritis: Insights from the RA Flare Questionnaire
Margaret Butler¹, Carlos Aude², Clifton Bingham³ and Vivian Bykerk¹, ¹Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ³Johns Hopkins University, Baltimore, MD
Background/Purpose: Elevated BMI has been previously associated with lower RA remission rates and underascertainment of swollen joint counts.1,2 However, a knowledge gap persists regarding the…
Abstract Number: 0974 • ACR Convergence 2023
Validation of Boolean 2.0 Criteria for Assessing Remission and Predicting Quality of Life in Korean Patients with Rheumatoid Arthritis Undergoing Targeted Therapy
Soo-Kyung Cho¹, Yeo-Jin Song¹, Jungyong Han², Hye Won Kim³, Eunwoo Nam³ and Yoon-Kyoung Sung¹, ¹Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ²Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ³Hanyang University Institute for Rheumatology Research, Seoul, South Korea
Background/Purpose: The management of rheumatoid arthritis (RA) focuses on achieving remission as a treatment goal. The updated ACR/EULAR remission definition (Boolean criteria 2.0) has raised…

« Previous Page
1
…
6
7
8
9
10
…
25
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].